About this item:

759 Views | 556 Downloads

Author Notes:

Address correspondence to L. Darrow, Emory University, 1518 Clifton Rd., Atlanta, GA 30322 USA. Telephone: (404) 727-4595. E-mail: ldarrow@emory.edu

We are grateful to the study participants and to the West Virginia Department of Health and Human Resources, Bureau for Public Health, Health Statistics Center; and the Ohio Department of Health, Center for Public Health Statistics and Informatics for the birth record data.

We also thank D. Savitz and T. Fletcher for their comments.

We are grateful to the study participants and to the West Virginia Department of Health and Human Resources, Bureau for Public Health, Health Statistics Center and the Ohio Department of Health, Center for Public Health Statistics and Informatics for the birth record data.

We also thank David Savitz and Tony Fletcher for their comments.

K.S. is one of three members of a Court approved C8 Science Panel established under the Settlement Agreement to determine if there are probable links (as defined in the Settlement Agreement) between PFOA and disease.

The authors declare they have no actual or potential competing financial interests.

Subjects:

Research Funding:

This research was funded by the C8 Class Action Settlement Agreement (Circuit Court of Wood County, West Virginia) between DuPont and Plaintiffs, which resulted from releases of perfluorooctanoic acid (PFOA, or C8).

Funds are administered by an agency that reports to the Court, and work is independent of either party to the lawsuit.

Serum Perfluorooctanoic Acid and Perfluorooctane Sulfonate Concentrations in Relation to Birth Outcomes in the Mid-Ohio Valley, 2005 to 2010

Tools:

Journal Title:

Environmental Health Perspectives

Volume:

Volume 121, Number 10

Publisher:

, Pages 1207-1213

Type of Work:

Article | Final Publisher PDF

Abstract:

Background: Previous research suggests perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) may be associated with adverse pregnancy outcomes. Objective: We conducted a population-based study of PFOA and PFOS and birth outcomes from 2005 through 2010 in a Mid-Ohio Valley community exposed to high levels of PFOA through drinking-water contamination. Methods: Women provided serum for PFOA and PFOS measurement in 2005–2006 and reported reproductive histories in subsequent follow-up interviews. Reported singleton live births among 1,330 women after 1 January 2005 were linked to birth records (n = 1,630) to identify the outcomes of preterm birth (< 37 weeks gestation), pregnancy-induced hypertension, low birth weight (< 2,500 g), and birth weight (grams) among full-term infants. Results: We observed little or no evidence of association between maternal serum PFOA or PFOS and preterm birth (n = 158) or low birth weight (n = 88). Serum PFOA and PFOS were both positively associated with pregnancy-induced hypertension (n = 106), with adjusted odds ratios (ORs) per log unit increase in PFOA and PFOS of 1.27 (95% CI: 1.05, 1.55) and 1.47 (95% CI: 1.06, 2.04), respectively, but associations did not increase monotonically when categorized by quintiles. Results of subanalyses restricted to pregnancies conceived after blood collection were consistent with the main analyses. There was suggestion of a modest negative association between PFOS and birth weight in full-term infants (–29 g per log unit increase; 95% CI: –66, 7), which became stronger when restricted to births conceived after the blood sample collection (–49 g per log unit increase; 95% CI: –90, –8). Conclusion: Results provide some evidence of positive associations between measured serum perfluorinated compounds and pregnancy-induced hypertension and a negative association between PFOS and birth weight among full-term infants.

Copyright information:

Publication of EHP lies in the public domain and is therefore without copyright.

Export to EndNote